Boston Scientific, a manufacturer of medical devices, offered to acquire the remaining 73% stake in Farapulse, a medical device company, for $387m. "We are encouraged by the positive reception to the commercial launch of the Farapulse PFA System in Europe, which we believe underscores the demand for a simpler way to treat AF. The strength and breadth of the Boston Scientific team will position this breakthrough technology for success and accelerate progress towards regulatory approval in the US," Allan Zingeler, Farapulse President and CEO.